Cargando…
COT-3 Exosomal microRNA expression signature in blood and cerebrospinal fluid of glioblastoma patients
Analysis of exosomes derived from plasma or cerebrospinal fluid (CSF) has emerged as a promising biomarker platform for therapeutic monitoring in glioblastoma patients. However, the contents of the various subpopulations of exosomes in these clinical specimens remain poorly defined. Here we characte...
Autores principales: | Yamashita, Daisuke, Suehiro, Satoshi, Ohtsuka, Yoshihiro, Ozaki, Saya, Nishikawa, Masahiro, Inoue, Akihiro, Kohno, Shohei, Ohue, Shiro, Ohnishi, Takanori, Kunieda, Takeharu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648223/ http://dx.doi.org/10.1093/noajnl/vdab159.111 |
Ejemplares similares
-
ANGI-2 Identification and functions of CD44 as a predictor for bevacizumab-resistant glioblastoma to optimally treat the tumor with bevacizumab
por: Inoue, Akihiro, et al.
Publicado: (2021) -
Hypoxia-induced phenotypic transition from highly invasive to less invasive tumors in glioma stem-like cells: Significance of CD44 and osteopontin as therapeutic targets in glioblastoma
por: Nishikawa, Masahiro, et al.
Publicado: (2021) -
Significance of Glioma Stem-Like Cells in the Tumor Periphery That Express High Levels of CD44 in Tumor Invasion, Early Progression, and Poor Prognosis in Glioblastoma
por: Nishikawa, Masahiro, et al.
Publicado: (2018) -
Is Interstitial Chemotherapy with Carmustine (BCNU) Wafers Effective against Local Recurrence of Glioblastoma? A Pharmacokinetic Study by Measurement of BCNU in the Tumor Resection Cavity
por: Ohnishi, Takanori, et al.
Publicado: (2022) -
CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
por: Nishikawa, Masahiro, et al.
Publicado: (2021)